PMID- 18688916
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 35
IP  - 9
DP  - 2008 Sep
TI  - Short-term influence of adalimumab on work productivity outcomes in patients with 
      rheumatoid arthritis.
PG  - 1729-36
AB  - OBJECTIVE: To evaluate the shortterm effect of adalimumab on work productivity in 
      patients with moderate to severe active rheumatoid arthritis (RA). METHODS: In a 
      substudy of the Canadian Adalimumab Clinical Trial (CanAct), clinical, health 
      status, and productivity outcomes were measured at baseline and 12 weeks. 
      Patients were classified as responders and nonresponders by the 20% American 
      College of Rheumatology (ACR20) improvement criterion and the minimum clinically 
      important difference (MCID) of the Health Assessment Questionnaire (HAQ) score 
      (0.22), respectively. The Health and Labour Questionnaire (HLQ) was used to 
      measure productivity outcomes and costs. RESULTS: Included in the analysis were 
      389 patients completing both baseline and 12-week HLQ questionnaire. Absenteeism 
      (a decrease of 0.5 workdays per 2 weeks) and unpaid work productivity (3.5 fewer 
      hours unpaid help per 2 weeks) were improved significantly after 12 weeks. 
      Improvements in productivity outcomes were associated with clinical response. 
      Bootstrapping results suggest that responders achieved statistically significant 
      improvement in presenteeism (ACR20) and unpaid work productivity (ACR20 and HAQ) 
      versus nonresponders. The costs saved by responders were up to $155.04 per 2 
      weeks more than those by nonresponders. CONCLUSION: The costs of adalimumab were 
      partially offset, even in the short term, by cost savings induced by clinical 
      response among Canadian patients with moderate to severe RA. These findings 
      complement results of other study analyses that demonstrate early and sustained 
      benefits of adalimumab.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, 
      Vancouver, British Columbia, Canada.
FAU - Bansback, Nick
AU  - Bansback N
FAU - Guh, Daphne
AU  - Guh D
FAU - Li, Xin
AU  - Li X
FAU - Nosyk, Bohdan
AU  - Nosyk B
FAU - Marra, Carlo A
AU  - Marra CA
FAU - Anis, Aslam H
AU  - Anis AH
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
DEP - 20080801
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - *Absenteeism
MH  - Adalimumab
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Efficiency/*drug effects
MH  - Employment/economics
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Physical Fitness
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Work Capacity Evaluation
EDAT- 2008/08/09 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/08/09 09:00
PHST- 2008/08/09 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/08/09 09:00 [entrez]
AID - 08/13/083 [pii]
PST - ppublish
SO  - J Rheumatol. 2008 Sep;35(9):1729-36. Epub 2008 Aug 1.